At the news
? NEUTRALIMPACT 3/10 144 filed Nov 2, 2026 at 16:39 ET
Director Lawrence Klein filed a Form 144 notice of intent to sell 25,000 shares of Oruka Therapeutics common stock, with an estimated aggregate market value of approximately $2.42 million based on the filing price. The sale is planned for November 2, 2026, and the shares were acquired through the exercise of stock options. Klein has a history of recent sales under a 10b5-1 plan, including 75,000 shares sold on September 1, 2026, and 25,000 shares sold on October 1, 2026, totaling over $9 million in recent dispositions.
- Director Lawrence Otto Klein filed Form 144 to sell 25,000 shares of Oruka Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is $2,421,750.
- Shares were acquired via exercise of stock options on November 2, 2026.
- Klein has sold 100,000 shares in the prior two months under a 10b5-1 plan (75,000 on Sep 1, 2026 and 25,000 on Oct 1, 2026).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access